Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast in Japanese pediatric patients with perennial allergic rhinitis
2014-004871-22Phase 3
- Sponsor
- Merck & Co.
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of montelukast in perennial rhinitis (2 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability and Pharmacokinetics.
02
Drugs
montelukast
03
Conditions
perennial rhinitis
Beyond the preview
Go deeper on 2014-004871-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004871-22.